Aptamers are typically found using an in vitro selection technique known as systematic evolution of ligands by exponential enrichment (SELEX). This process involves multiple repetitive rounds of partitioning and enzymatic amplification. Due to the limited chemical diversity of nucleic acids, especially when compared to proteins, numerous SELEX experiments have been performed with modified nucleotides in an effort to enhance aptamer-target interactions. These experiments have been successful; however, the use of nucleic acid modifications during SELEX is rather limited. Each modified nucleotide that is used in SELEX must be a compatible substrate for polymerases and will completely replace its unmodified equivalent. Herein, a one-round, bead-based aptamer selection process will be described that eliminates enzymatic amplification of candidate oligonucleotides. Due to the solid phase synthesis of the libraries, this selection process is extraordinarily flexible in terms of what modifications can be used and how many of each modification is used. For example, one single bead-based library can include all of the R-groups of the twenty most common amino acids!The bead-based selection is accomplished using a simple and rapid two-stage process that can be completed within one week without the use of any specialized equipment. The first stage involves the magnetic pull-down of library beads with labeled target, and the second involves magnetic pull-down of the modified oligonucleotides released into solution from the selected beads. This two-stage selection can be carried out against several targets simultaneously. PCR is used to create unmodified DNA replicates (i.e., bar codes) of the selected modified sequences and next generation sequencing and bioinformatics analysis are performed to identify X-Aptamer candidates for resynthesis. In this manner, X-Aptamers routinely exhibiting nanomolar affinity have been successfully developed against a long list of targets that include P. falciparum LDH, HIV p24, osteoprotegerin, HSA, myotoxin as well as his-tag.The simplicity of X-Aptamer development has allowed the process to be packaged into a kit. This selection kit enables virtually any laboratory scientist to rapidly develop his or her own X-Aptamers. The kit contains a bead-based library and multiple bar-coded primers that allow for the use of up to three targets. The customer performs the two-stage selection and then PCR amplifies the selected material using unmodified nucleotides. The PCR product, which is comprised of unmodified DNA, is then sent to AM Biotech for sequencing. AM Biotech identifies the candidate X-Aptamers from the sequencing data, resynthesizes them with the appropriate modifications and sends the X-Aptamers to the customer for affinity validation. To date, β-tests of the selection kit have been very successful.
Read full abstract